These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 18726098)

  • 1. A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma.
    Uhm JE; Park JO; Lee J; Park YS; Park SH; Yoo BC; Paik SW; Koh KC; Kang WK; Lim HY
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):929-35. PubMed ID: 18726098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.
    Lee J; Park JO; Kim WS; Park SH; Park KW; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC; Joh J; Kim K; Jung CW; Park YS; Im YH; Kang WK; Lee MH; Park K
    Cancer Chemother Pharmacol; 2004 Nov; 54(5):385-90. PubMed ID: 15248028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of hepatic arterial infusion of oxaliplatin in advanced hepatocellular cancer: a brown university oncology group study.
    Rathore R; Safran H; Soares G; Dubel G; McNulty B; Ahn S; Iannitti D; Kennedy T
    Am J Clin Oncol; 2010 Feb; 33(1):43-6. PubMed ID: 19687731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
    Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
    Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.
    Boige V; Raoul JL; Pignon JP; Bouché O; Blanc JF; Dahan L; Jouve JL; Dupouy N; Ducreux M;
    Br J Cancer; 2007 Oct; 97(7):862-7. PubMed ID: 17876335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial.
    Yen Y; Lim DW; Chung V; Morgan RJ; Leong LA; Shibata SI; Wagman LD; Marx H; Chu PG; Longmate JA; Lenz HJ; Ramanathan RK; Belani CP; Gandara DR
    Am J Clin Oncol; 2008 Aug; 31(4):317-22. PubMed ID: 18845988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.
    Cheng AL; Yeh KH; Fine RL; Chuang SE; Yang CH; Wang LH; Chen DS
    Hepatogastroenterology; 1998; 45(24):1955-60. PubMed ID: 9951847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
    Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
    Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma.
    Hong RL; Tseng YL
    Cancer Chemother Pharmacol; 2003 May; 51(5):433-8. PubMed ID: 12736762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with Child-Pugh B cirrhosis.
    Dhooge M; Coriat R; Mir O; Perkins G; Brezault C; Boudou-Rouquette P; Goldwasser F; Chaussade S
    Oncology; 2013; 84(1):32-8. PubMed ID: 23076239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
    Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
    Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer.
    Chen JS; Rau KM; Chen YY; Huang JS; Yang TS; Lin YC; Liau CT; Lee KD; Su YC; Kao RH
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):819-25. PubMed ID: 18663448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dose-escalation study of pegylated liposomal Doxorubicin and oxaliplatin in patients with advanced solid tumors.
    Kotsakis A; Kouroussis Ch; Androulakis N; Agelaki S; Kalbakis K; Vamvakas L; Vardakis N; Kalykaki A; Polyzos A; Georgoulias V; Mavroudis D
    Oncology; 2006; 71(3-4):190-6. PubMed ID: 17641537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation.
    Lee JO; Kim DY; Lim JH; Seo MD; Yi HG; Oh DY; Im SA; Kim TY; Bang YJ
    J Gastroenterol Hepatol; 2009 May; 24(5):800-5. PubMed ID: 19175825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer.
    Cao W; Xu C; Lou G; Jiang J; Zhao S; Geng M; Xi W; Li H; Jin Y
    Jpn J Clin Oncol; 2009 Sep; 39(9):582-7. PubMed ID: 19509000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of epirubicin and etoposide combination chemotherapy in advanced hepatocellular carcinoma: a retrospective analysis.
    Lee JL; Ryu MH; Chang HM; Kim TW; Lee SS; Sym SJ; Kim MK; Kim KM; Lee JS; Kang YK
    J Gastroenterol Hepatol; 2008 May; 23(5):811-6. PubMed ID: 17995941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer.
    Zhao JG; Qiu F; Xiong JP; Zhang L; Xiang XJ; Yu F; Yan J; Zhan ZY; Feng M
    Anticancer Drugs; 2009 Apr; 20(4):281-6. PubMed ID: 19247179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrolamellar hepatocellular carcinoma in children and adolescents.
    Katzenstein HM; Krailo MD; Malogolowkin MH; Ortega JA; Qu W; Douglass EC; Feusner JH; Reynolds M; Quinn JJ; Newman K; Finegold MJ; Haas JE; Sensel MG; Castleberry RP; Bowman LC
    Cancer; 2003 Apr; 97(8):2006-12. PubMed ID: 12673731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer.
    Cao W; Yang W; Lou G; Jiang J; Geng M; Xi W; Li H; Ma T; Jin Y
    Anticancer Drugs; 2009 Apr; 20(4):287-93. PubMed ID: 19177020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
    Novarino A; Satolli MA; Chiappino I; Giacobino A; Bellone G; Rahimi F; Milanesi E; Bertetto O; Ciuffreda L
    Am J Clin Oncol; 2009 Feb; 32(1):44-8. PubMed ID: 19194124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.